|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 328.40 SEK | -0.97% |
|
-1.62% | -1.32% |
| Jan. 19 | SEB Raises Price Target for Sobi to 500 Kronor (400), Reiterates Buy | FW |
| Jan. 16 | Sobi's Rare Kidney Diseases Drug Lands Approval in Europe | MT |
| Capitalization | 113B 12.29B 10.56B 9.8B 9.15B 17.04B 1,117B 18.31B 44.58B 532B 46.1B 45.15B 1,943B | P/E ratio 2025 * |
-650x | P/E ratio 2026 * | 19.2x |
|---|---|---|---|---|---|
| Enterprise value | 123B 13.41B 11.52B 10.69B 9.99B 18.59B 1,219B 19.98B 48.63B 580B 50.29B 49.26B 2,120B | EV / Sales 2025 * |
4.33x | EV / Sales 2026 * | 3.7x |
| Free-Float |
51.66% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Swedish Orphan Biovitrum AB
| 1 day | -0.97% | ||
| 1 week | -1.62% | ||
| Current month | -1.32% | ||
| 1 month | +0.12% | ||
| 3 months | +5.39% | ||
| 6 months | +20.91% | ||
| Current year | -1.32% |
| 1 week | 322.8 |  | 360.6 |
| 1 month | 322.8 | | 360.6 |
| Current year | 322.8 | | 360.6 |
| 1 year | 241.8 | | 360.6 |
| 3 years | 197.9 | | 360.6 |
| 5 years | 127.1 | | 360.6 |
| 10 years | 89.5 | | 360.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Guido Oelkers
CEO | Chief Executive Officer | 61 | 2017-05-21 |
Henrik Stenqvist
DFI | Director of Finance/CFO | 59 | 2018-07-19 |
| Chief Tech/Sci/R&D Officer | 55 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Staffan Schüberg
BRD | Director/Board Member | 57 | 2019-12-31 |
| Director/Board Member | 70 | 2020-12-31 | |
Filippa Stenberg
BRD | Director/Board Member | - | - |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +2.20% | 1.15% | 285 M€ | |
| +1.36% | 0.9% | 4 M€ | |
| -.--% | 0.48% | 0 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.97% | -1.62% | -0.73% | +43.78% | 12.38B | |
| -1.20% | -4.55% | +7.55% | +2.44% | 75.21B | |
| -0.92% | +94.70% | +94.70% | +94.70% | 61.16B | |
| -2.90% | +2.38% | +40.81% | +232.95% | 58.53B | |
| +0.87% | +2.75% | -35.14% | -40.44% | 56.54B | |
| -2.46% | -11.43% | +16.98% | -41.31% | 24.12B | |
| +0.92% | -0.11% | +47.66% | +26.62% | 20.85B | |
| -0.41% | -4.86% | +174.07% | +100.24% | 19.91B | |
| +10.10% | +1.37% | +68.46% | +1,361.21% | 18.8B | |
| +6.28% | +23.61% | +22.81% | -78.03% | 16.34B | |
| Average | +0.95% | +1.33% | +43.72% | +170.22% | 36.38B | |
| Weighted average by Cap. | -0.08% | +0.09% | +36.50% | +120.20% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 28.53B 3.1B 2.66B 2.47B 2.31B 4.29B 282B 4.61B 11.24B 134B 11.62B 11.38B 490B | 31.66B 3.44B 2.95B 2.74B 2.56B 4.77B 312B 5.12B 12.47B 149B 12.89B 12.63B 544B |
| Net income | -253M -27.45M -23.58M -21.88M -20.44M -38.05M -2.49B -40.89M -99.55M -1.19B -103M -101M -4.34B | 5.7B 619M 531M 493M 461M 857M 56.21B 921M 2.24B 26.76B 2.32B 2.27B 97.79B |
| Net Debt | 10.3B 1.12B 961M 891M 833M 1.55B 102B 1.67B 4.06B 48.39B 4.19B 4.11B 177B | 3.97B 431M 370M 344M 321M 598M 39.19B 642M 1.56B 18.66B 1.62B 1.58B 68.18B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-19 | 328.40 kr | -0.97% | 433,655 |
| 26-01-16 | 331.60 kr | -2.47% | 525,975 |
| 26-01-15 | 340.00 kr | -0.41% | 1,363,173 |
| 26-01-14 | 341.40 kr | +1.73% | 627,977 |
| 26-01-13 | 335.60 kr | +0.54% | 478,261 |
Delayed Quote Nasdaq Stockholm, January 19, 2026 at 12:00 pm EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SOBI Stock
Select your edition
All financial news and data tailored to specific country editions
